New cell therapy tested for Life-Threatening transplant complication
NCT ID NCT04744116
Summary
This early study is testing whether adding special cells from donated umbilical cord blood to the standard drug ruxolitinib works better than the drug alone. It aims to help cancer patients (ages 12-80) who develop a severe, steroid-resistant immune reaction called graft-versus-host disease after a bone marrow or stem cell transplant. Researchers will compare three groups: one gets just the drug, and two others get the drug plus one of two different doses of the cord blood cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.